144 results on '"Berenguer, Jordi"'
Search Results
2. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
3. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
4. Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer
5. Correction to: The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
6. Sensing of latent EBV infection through exosomal transfer of 5′pppRNA
7. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
8. Gabriel Ferraté (ex-rector UPC), Jordi Hernández, Javier Bará Temes i José Luis Andrés Yebra parlant entre ells durant l'acte de celebració
9. PROYECTO DE AUTOMATIZACIÓN DEL TRANSPORTE DE PRODUCTO FINAL MEDIANTE ROBOTS AUTÓNOMOS MÓBIL MiR
10. Cell memory of epithelial-mesenchymal plasticity in cancer
11. PROYECTO DE AUTOMATIZACIÓN DEL TRANSPORTE DE PRODUCTO FINAL MEDIANTE ROBOTS AUTÓNOMOS MÓBIL MiR
12. Introducing Cloned Genes into Cultured Neurons Providing Novel In vitro Models for Neuropathology and Neurotoxicity Studies
13. Altered Lignin Biosynthesis Improves Cellulosic Bioethanol Production in Transgenic Maize Plants Down-Regulated for Cinnamyl Alcohol Dehydrogenase
14. SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
15. Abstract B03: Urine cell-free DNA (cfDNA) concentration and stability test for future clinical use
16. Probucol Increases Glutathione Peroxidase-1 Activity and Displays Long-Lasting Protection against Methylmercury Toxicity in Cerebellar Granule Cells
17. BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale
18. Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
19. PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer
20. Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
21. Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
22. A High-Efficiency RF Harvester with Maximum Power Point Tracking
23. Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8
24. Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8
25. AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC.
26. IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKCι inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC).
27. Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8
28. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
29. STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
30. The combination of checkpoint immunotherapy and targeted therapy in cancer
31. Analysis of the Optimum Gain of a High-Pass L-Matching Network for Rectennas
32. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer
33. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer
34. Sensing of latent EBV infection through exosomal transfer of 5'pppRNA
35. In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior
36. In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior
37. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer
38. Control de la proliferación de células granulares de cerebelo mediado por microRNAs
39. Abstract LB-053: Monitoring rearrangement of EML4-ALK in blood platelets predicts outcome to crizotinib treatment in non-small-cell lung cancer patients
40. EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients.
41. In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior
42. La Televisió digital terrestre: un color millor... i alguns grisos
43. MicroRNA 22 regulates cell cycle length in cerebellar granular neuron precursors
44. Fotografia amb Gabriel Ferraté Pasqual (ex-rector UPC), Joan Majó Roca (ex-vicerector) i Francesc Solà Busquets (ex-gerent UPC)
45. Fotografia de José Luis Andrés Yebra (Ex-director EPSC)
46. Altered lignin biosynthesis improves cellulosic bioethanol production in transgenic maize plants down-regulated for cinnamyl alcohol dehydrogenase
47. Fotografia de Jordi Berenguer, director de l'EETAC
48. Jordi Hernández, Javier Bará Temes, José Luis Andrés Yebra (aquest tercer tapat per en Josep M. Oliveres, persona d'esquena) i Gabriel Ferraté, tots junts parlant entre ells
49. Fotografia en família de Jaume Sanz Subirana, Eduard Bertrán, Javier Bará, Jordi Berenguer (director de l'EETAC) i Jordi Hernández
50. Fotografia de José Luis Andrés Yebra i Javier Bará Temes, exdirectors de l'Escola
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.